Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma

In this episode, Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, discuss various strategies to optimize the use of bispecific antibodies in their practices for the treatment of R/R MM through patient monitoring, dosing in outpatient settings, and using tocilizumab and IVIG, among other management strategies. 

Presenters: 

Muhamed Baljevic, MD, FACP
Associate Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Director, Multiple Myeloma Program
Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP)
Co-Chair, Scientific Review Committee, VICC
Disease Team Lead, Plasma Cell Dyscrasias and Lymphomas
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, Tennessee

Jonathan Ticku, MD
Medical Oncologist and Hematologist
GU Oncology Lead, Mayo Clinic Health System
Assistant Professor of Oncology, Mayo Clinic
La Crosse, Wisconsin

Link to full program: 
https://bit.ly/4u0xH6q

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.